Crinetics Pharmaceuticals
CRNX
235 hedge funds and large institutions have $4.32B invested in Crinetics Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 97 increasing their positions, 74 reducing their positions, and 27 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 74
17% more capital invested
Capital invested by funds: $3.69B → $4.32B (+$627M)
1% more ownership
Funds ownership: 104.6% → 105.61% (+1%)
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
0% more funds holding
Funds holding: 234 → 235 (+1)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
30% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.3M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$31.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$27.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$47.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$38.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.8M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$19.1M |
| 5 |
SC
Stempoint Capital
New York
|
-$17.4M |
CRNX Hedge Fund Activity: Q3 2024 in Review
235 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2024, worth a combined $4.32B — up 17% from $3.69B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRNX positions and 27 closed out — a net gain of 1 holder — while 97 added to existing stakes and 74 trimmed.
The largest buyer was Vanguard Group, adding an estimated $91.5M. The largest seller was Artal Group, exiting entirely with an estimated $47.7M sold.
- 235 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2024, up from 234 in Q2 2024.
- Funds reported $4.32B of Crinetics Pharmaceuticals stock for Q3 2024, up 17% quarter-over-quarter.
- 28 funds opened new Crinetics Pharmaceuticals positions in Q3 2024 and 27 closed out, a net change of +1 holder.
- The largest Crinetics Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $91.5M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2024 was Artal Group, an estimated $47.7M sold.
Based on aggregated 13F filings for Q3 2024.